AbCellera Biologics Inc. (ABCL) shares rallied 15% in the last trading session to close at $5.15. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 31.4% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism related to the company’s progress with its pipeline candidate, ABCL635, a first-in-class antibody that is being developed for the non-hormonal treatment of vasom ...